Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.
about
Fibulin-3 as a biomarker of response to treatment in malignant mesotheliomaClinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma.Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma.
P2860
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@ast
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@en
type
label
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@ast
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@en
prefLabel
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@ast
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@en
P2093
P2860
P356
P1476
Polymorphisms in folate pathwa ...... alignant pleural mesothelioma.
@en
P2093
Katja Goricar
Viljem Kovac
Vita Dolzan
P2860
P304
P356
10.2478/RAON-2013-0086
P577
2014-04-25T00:00:00Z